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Summary This study aims to select the radiopharmaceutical vehicle for targeted radiotherapy of neuroblas-
toma which is most likely to penetrate readily the centre of micrometastases in vivo. The human neuroblas-
toma cell line NB1-G, grown as multicellular spheroids, provided an in vitro model for micrometastases. The
radiopharmaceuticals studied were the catecholamine analogue metaiodobenzyl guanidine (mIBG), a specific
neuroectodermal monoclonal antibody (UJ13A) and P nerve growth factor (PNGF). Following incubation of
each drug with neuroblastoma spheroids, autoradiographs of frozen sections were prepared to demonstrate
their relative distributions. mIBG and PNGF were found to penetrate the centre of spheroids readily although
the concentration of mIBG greatly exceeded that of PNGF. In contrast, UJ13A was only bound peripherally.
We conclude that mIBG is the best available vehicle for targeted radiotherapy of neuroblastoma cells with
active uptake mechanisms for catecholamines. It is suggested that radionuclides with a shorter range of
emissions than '3'I may be conjugated to benzyl guanidine to constitute more effective targeting agents with
potentially less toxicity to adjacent normal tissues.
Neuroblastoma is a solid malignant tumour of childhood.
Although it is relatively radiosensitive, local radiotherapy
alone for neuroblastoma is often inadequate because of the
propensity of the tumour for early systemic spread. Some
neuroblastoma cells have biochemical peculiarities which
enable preferential concentration of catecholamine pre-
cursors; they may also express antigens against which mono-
clonal antibodies have been prepared. Neuroblastoma is
therefore regarded as one of the best candidates for targeted
radiotherapy (Lashford et al., 1988). It is possible that this
form of treatment will be more effective in the eradication of
small tumour deposits rather than bulky disease (Kemshead
et al., 1987).
Since neuroblastoma arises from undifferentiated sympa-
thetic nerve cells, these tumours are often able to accumulate
and store catecholamines more readily than other tissues.
This property has lead to the use of the radiopharmaceutical
compound metaiodobenzyl guanidine (mIBG), an analogue
of the adrenergic neurone blocking drug guanethidine, for
the detection, staging and treatment of neuroblastoma (Beier-
waltes, 1987). Selective absorption of this drug is thought to
be achieved mainly by an active transport process (Jaques et
al., 1984) which is sensitive to desmethylimipramine and
ouabain (Jaques et al., 1987).
The potential of monoclonal antibodies to target tumours
continues to be the focus of much research. One such anti-
body, UJ13A, binds specifically to neuroectodermal antigens
(Allan et al., 1983; Kemshead, 1985). It has affinity for
human neuroblastoma and, when conjugated with '3'I, has
been shown to retard the growth of neuroblastoma spheroids
(Walker et al., 1988). However attempts to treat patients with
neuroblastoma by intravenous administration of '3'I-labelled
UJ13A have been hampered by slow clearance of the anti-
body from blood resulting in poor concentration of radio-
activity in tumour sites (Kemshead et al., 1985).
A third possible way in which radionuclides can be target-
ed into neuroblastoma utilises their expression of nerve
growth factor receptor which is widely found in neuroblas-
toma cell lines (Sonnenfeld & Ishii, 1982). The level of ex-
pression in tumours is often very much higher than in the
corresponding normal cell (Fabricant et al., 1977).
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An increase in the therapeutic potential of targeting anti-
bodies or drugs should be achievable by the replacement of
long range P-emitters such as 13'1 with short range a-emitters,
such as the highly radiotoxic halogen astatine (2"At) (Humm,
1986). However the effectiveness of agents labelled in this
way will be dependent upon their penetration into tumours.
We have therefore compared the ability of radioiodinated
mIBG, UJ13A and PNGF to penetrate into multicellular
tumour spheroids of a neuroblastoma cell line.
Materials and methods
Cell lines
The human neuroblastoma cell line used as a model of
micrometastases in this study was NBI-G. The biological
properties of this line, recently established from a child with
stage IV neuroblastoma, have been reported by Carachi et al.
(1987). We have subsequently demonstrated that this cell line
exhibits temperature, sodium and energy dependent active
uptake (uptake-one) of mIBG, which can be blocked by
ouabain, desmethylimipramine and excess norepinephrine,
similar to that seen in adrenal medullary cells (Jaques et al.,
1984), phaeochromocytoma cells (Jaques et al., 1987) and in
other neuroblastoma cells lines (Smets et al., 1989; Paffenholz
et al., 1989). In addition, we have demonstrated that this line
also shows binding of radiolabelled PNGF, which is compet-
itively blocked by excess of unlabelled PNGF, but not by
similar quantities ofcytochrome C, a molecule of similar size
and charge. This indicates that binding of PNGF to NBI-G
cells is a specific process mediated by nerve growth factor
receptors (Stach & Perez-Polo, 1987).
Another cell line, A2780, was used as a negative control
because it was not of neural crest origin. This line, kindly
supplied by Dr R.F. Ozols of the National Cancer Institute,
Bethesda, Maryland, was derived from human ovarian car-
cinoma, and is a variant of the cell line NIH:OVCAR-3
(Hamilton et al., 1983).
Culture conditions
All cells were grown at 37°C in 5% CO2 in Eagle's Minimal
Essential Medium containing 25 mM Hepes buffer, 15%
foetal calf serum, 2 mM glutamine, penicillin/streptomycin
(100 IUml-') and amphotericin B (2.5 tgml1'). All media
and supplements were obtained from Gibco (Paisley, UK).
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Reagents
'3'I-mIBG (specific activity 37-185 MBq mg-' or > 1110
MBq mg-') was obtained from Amersham International
(Amersham, UK). '25I-mIBG was prepared as described by
Moyes et al. (1989), from cold mIBG (IK4 kit, CIS, France)
using solid phase ion exchange. The radiochemical purity was
greater than 95%, as determined by thin layer chromato-
graphy and high performance liquid chromatography.
The neuroectodermal antigen-specific monoclonal anti-
body, UJ13A, was kindly supplied by Dr J.T. Kemshead,
ICRF Laboratories, Frenchay Hospital, Bristol. It was
labelled by the iodogen method using carrier free Na('25I)
(Amersham International plc). Following the incubation of
100 jig protein with '25I, the efficiency of binding of radio-
iodine was shown by thin layer chromatography to be greater
than 80%.
The ,-subunit of nerve growth factor (PNGF) was isolated
from male mouse submaxillary salivary glands according to
the method of Mobley et al. (1976) and was further purified
by column chromatography. Electrophoresis and HPLC were
used to ensure that the PNGF was pure. Radiolabelling was
performed as with UJ13A. Thin layer chromatography dem-
onstrated the efficiency of binding to be in excess of 70%.
Determination ofpenetrability
Multicellular tumour spheroids were prepared by continuous
stirring of NB1-G cells (2 x 104 cells ml-') in Techne (Cam-
bridge, UK) stirrer flasks for 3-7 days at 37°C, 5% CO2.
NB1-G spheroids with a diameter greater than 300jim were
incubated at 37°C with gentle mixing (Multimix Roller,
Luckham Ltd) for 10, 60 or 120 min in culture medium
containing 0.14 MBq ml-' of '251I-mIBG (specific activity
41.7 MBq mg-'), '251-UJ13A (specific activity 21.7 MBq
100 ig'-) or '25I-PNGF (specific activity 18.7 MBq 100jig-').
They were then washed three times in culture medium,
embedded in mounting medium on cutting blocks and frozen
by cooling to - 30°C. The time between the end of the
incubation period and freezing was 60 min. Twenty jim sec-
tions were cut in a Bright OTF/AS cryostat at - 30°C,
transferred to microscope slides and dried on a hot plate at
60°C. The sections were then sealed in cassettes in contact
with Kodak PE205 X-ray film for 4 to 14 days before
developing. Autoradiographic standards of similar thickness
and containing known concentrations of 1251 (Amersham
International) were exposed to the same film. Quantitation of
isotopic concentration was achieved by measurement of the
optical density of autoradiograms using an image analyser
(MCID, Imaging Research Inc). Sections were stained with
haemotoxylin and eosin for comparison with the autoradio-
grams.
In addition to autoradiography, fluorescent microscopy
was also used to assess the penetration of UJ13A into
spheroids. For this, similarly preincubated spheroids were
washed, frozen and sectioned as described above, and incu-
bated for 2 h with the fluorescein isothiocyanate-conjugated
anti-mouse IgG (whole molecule) antibody (Sigma, Poole,
UK). After thorough rinsing with phosphate buffered saline
to remove any unbound traces of the second antibody, sec-
tions were examined under UV illumination to show distribu-
tion of the antibody.
Controls
To investigate whether antigen expression was uniform
throughout NB1-G spheroids, precut spheroids frozen sec-
tions sections were incubated with '251-labelled-UJ13A
(0.14 MBq ml-') for 2 h. After being thoroughly washed to
remove unbound antibody, sections were autoradiographed
as described previously. Further precut sections were incu-
bated with non-radiolabelled UJ13A, and the distribution of
antibody (representing the sites of antigen expression) exam-
ined both by fluorescent microscopy as above and also by an
immunoperoxidase staining technique. The latter was per-
formed on sections of both frozen and formalin fixed,
paraffin embedded sections. For frozen section, spheroids
were embedded in Cryomatrix mounting medium (Shandon
Southern Products Ltd) and frozen with compressed CO2
Sections, 7 jm thick, were cut on a cryostat at -24°C and
fixed for 10min in acetone. For paraffin sections, spheroids
were fixed in 10% neutral buffered formalin and embedded in
paraffin wax using standard techniques. Sections, 2 tm thick,
were cut, mounted on poly-L-lysine coated slides and were
dewaxed in xylene. For immunostaining, sections were
incubated overnight with UJ13A (at a dilution of 1:20 for
paraffin sections, and 1:120 for frozen sections), and stained
using a biotin/ avidin/peroxidase technique (Vectasain ABC
Kit, Vector Laboratories, Burlinghame, CA).
To ensure that any observed binding of antibody was
specific for the NB1-G cell line, experiments were repeated
with the ovarian carcinoma cell line, A2780.
Results
Histological examination of haematoxylin and esoin stained
NB1-G small spheroid sections revealed an even distribution
of mitotic centres. No confluent necrosis was apparent in
spheroids of diameter less than 400 im, although there was
evidence of necrosis of single cells which showed nuclear
pyknosis (Figure 1). Larger spheroids, however, exhibited
central necrotic regions with a peripheral rim of viable cells
approximately 200 Lm thick (Figure 2).
Incubations of NBI-G spheroids of 300-4001am diameter
with '251I-labelled targeting agents and subsequent autoradio-
graphy of 20fjm thick spheroid sections revealed uniform
distribution of mIBG and PNGF whereas UJ13A localisation
occurred predominantly on the surface of the spheroids
(Figure 1). Subviable regions in larger spheroids (of diameter
>500jIm) were associated with reduced uptake of mIBG
(Figure 2).
The mean ( s.d.) concentrations of 1251I-mIBG were 0.09
(0.01), 0.63 (0.07)and 1.12 (0.20) MBqg-' after 10, 60 and
120 min incubatioh respectively. '25I-,NGF was also uni-
formly distributed, but at a much lower concentration
(2-3% of that of mIBG). '251-UJl3A was bound predomin-
antly in a thin layer around the periphery of spheroids, with
little penetration to the interior (3-4% relative to mIBG) -
see Table I. Prolonged incubation (24 h) of spheroids with
PNGF did not result in uptake levels greater than that seen
at 2 h. Binding of antibody only to the periphery was also
observed by fluorescent microscopy of spheroids sectioned
after incubation with UJ13A (Figure 3a).
In order to determine whether peripheral antibody binding
to spheroids was a consequence ofdifferential antigen expres-
sion between surface cells and those located in the interior,
spheroids of various diameters (100-600 1im) were sectioned
and exposed to '251I-UJl3A for 2 h. Autoradiographs showed
almost uniform binding of antibody throughout the cross-
section (Figure 4). Similarly, fluorescent microscopy (Figure
3b) and immunoperoxidase staining of precut sections incu-
bated with unlabelled antibody both revealed binding of
UJ13A throughout the sections, whereas binding to the
A2780 control spheroids only occurred non-specifically in the
necrotic regions. Therefore the inefficient concentration of
UJ13A in the deeper portions of NBI-G spheroids appears
to be due to an inability of the monoclonal antibody to
penetrate beyond the outer cell layers.
Discussion
The principal limitation of radiotherapy as a curative moda-
lity is the limited radiation tolerance of normal tissues. If a
tumour is clearly circumscribed it is often possible to deliver
a curative dose of radiation without causing critical damage
to adjacent normal tissues. However many tumours have a
propensity for early systemic spread, making curative local
irradiation impossible. Wide field and whole body radio-406 R.J. MAIRS et al.
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Figure 1 Twenty !4m frozen sections of 300-400 gm diameter NB1-G spheroids treated for 2 h with 0.14 MBqml-' a, '25I-mIBG
(specific activity 41.7 MBqmg'), b, 1251-UJI3A (specific activity 21.7 MBq 100jg-' protein) or c, '25I-PNGF (specific activity
18.7 MBq I00 tg-'). Haematoxylin-eosin stained sections with corresponding autoradiographs. Bars = 100 m.TARGETING OF NEURBLASTOMA SPHEROIDS 407
Figure 2 Twenty jAm frozen section of 500 lm diameter NBI-G spheroid treated with '25I-mIBG as described in legend to Figure
1. Haematoxylin-eosin stained section with corresponding autoradiograph. Bars= 100 Am.
Table I Accumulation of '25I-labelled targeting agents in the interiors
of NBI-G spheroids as determined by image analysis of autoradio-
grams
Incubation time (min) Uptake* (MBqg-')
mIBG 10 0.085±0.011
60 0.625±0.074
120 1.12±0.020
PNGF 120 0.027±0.004
UJI3A 120 0.037±0.018
*Radioactivity located in the interior of spheroids determined by
image analysis ofautoradiograms. Means± s.d. ofsix determinations.
therapy may adequately encompass all tumour deposits, but
because of the large amount of normal tissue inevitably
irradiated along with the tumour, these methods are success-
ful only in eliminating small numbers of radiosensitive cells.
In principle, the two problems of normal tissue tolerance and
tumour dissemination may be circumvented by targeted
radiotherapy. In this approach, drugs which are preferentially
concentrated in tumour tissue are conjugated to radionuc-
lides and administered systemically. Ideally radiation would
be delivered to the all tumour cells, wherever in the body
they may be, and healthy tissue would be spared. In practice,
however, the conditions for targeted radiotherapy are far
from ideal.
Of the various cell lines available we have chosen NB1-G
for our in vitro studies of targeting agents with potential for
use against human neuroblastoma because it shows ouabain-
sensitive active uptake (uptake-one) of mIBG, particularly at
low concentrations. In addition, NBI-G expresses both neu-
roectodermal antigens and nerve growth factor receptor and
readily forms multicellular spheroids which constitute a good
model of avascular micrometastases for in vitro studies of
penetration by targeting agents.
We have demonstrated the superior penetration of radio-
labelled mIBG relative to the monoclonal antibody UJ13A
into human neuroblastoma spheroids. However, since the
P-particle range of '"'I is sufficiently great to allow the
irradiation of every cell within a 3001m spheroid, poor
penetration of UJ13A would not necessarily render it inappli-
cable as a targeting agent for the sterilisation of micrometas-
tases whose proliferating cells tend to be concentrated near
the periphery. Indeed Walker et al. (1988) have demonstrated
that '31I-UJ13A can cause growth delay in NBI-G spheroids.
Poor penetration of whole immunoglobulins is only likely to
Figure 3 Fluorescent microscopy of UJ13A bound to a, spher-
oid pre-incubated with UJ13A then cut and b, precut NBI-G
spheroid section.
become a serious problem when attempting to target larger
tumours.
In addition to mIBG and monoclonal antibody as agents
for targeting radiotherapy in neuroblastoma, the possibility
of using PNGF is suggested by the finding that many neuro-
blastoma cell lines possess the relevant receptor (Baker et al.,408 R.J. MAIRS et al.
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Figure 4 Autoradiographic localisation of UJI3A bound to pre-
cut NB1-G spheroid section.
1989). The fact that most cases of neuroblastoma do not
differentiate to maturity suggests, however, that they have
acquired the capacity to grow and survive in the absence of
nerve growth factor (Sonnenfeld & Ishii, 1982). We have
shown that although pNGF was distributed uniformly
throughout spheroids, it was concentrated to a much lesser
degree than mIBG, and so is less likely to be a useful vehicle
for delivering therapeutic radiation in clinical practice. A
further possible limitation to the use of,BNGF as a radio-
pharmaceutical in man is the tolerance of normal tissues
which might also concentrate the drug. The normal anatom-
ical distribution of nerve growth factor receptors in humans
at various stages of development has not, however, been
described. The principle sites of receptor expression in neo-
natal rats are the sympathetic and sensory (dorsal root)
ganglia in the periphery, and the septum-basal forebrain
centrally. Levels in adult rats are higher in the basal fore-
brain and sympathetic ganglia and lower in sensory ganglia
(Buck et al., 1987).
Effective targeted radiotherapy requires an adequate dose
of radiation to be delivered to all tumour cells. This depends
not only upon the distribution of the drug within the patient,
but also on the physical characteristics of the radionuclide
borne by the drug. Whether cells which fail to accumulate
the targeting agent escape irradiation completely depends on
the maximum distance between targeted and untargeted cells
in relation to the range of radiation emitted during radionu-
clide disintegration.
Because about two thirds of the energy released by the
disintegration of '"'I is in the form of highly penetrating
y-rays, this radionuclide is far from ideal for targeting
precision, and alternative radionuclides for use in targeted
radiotherapy have been proposed (Humm, 1986). One alter-
native which is already being investigated for treatment of
malignant melanoma in experimental animals is the halogen,
astatine (2"At) (Link et al., 1989). This isotope is a short
range a-particle emitter, and ifall cells are not targeted, 'cold
spots' in the tumour may become a problem as there is not
enough crossfire from targeted to untargeted cells to lead to
their erradication. The results of our penetration studies
suggest that whole immunoglobulin molecules may for this
reason, be inappropriate targeting vehicles if the conjugated
radionuclide is a short range emitter. On the other hand,
radio-astatinated benzyl guanidine (2"At-mABG) could be a
more effective radiopharmaceutical than its radioiodinated
counterpart, provided that the specificity ofuptake is not lost
as a result of bonding of this bulkier atom to benzyl
guanidine. The short physical half life of 2"At (7.2 h) may
however introduce problems in this approach to reduce the
dose absorbed by normal tissues. If there is inadequate time
for clearance of the drug from normal tissues before the bulk
of radionuclide decay takes place, then the whole body dose
will be increased and the ratio oftumour dose to non-tumour
dose diminished. It is conceivable that this could more than
offset the benefit of reduced normal tissue dose from radia-
tion emanating from within the tumour tissue. These studies,
however, provide encouragement for the continued investiga-
tion of small molecules in preference to immunoglobulins as
delivery agents for targeted radiotherapy. Antibody frag-
ments, both Fab and F(ab')2 fragments produced by cleavage
of the immunoglobulin by papain and pepsin digestion
respectively, have theoretical attractions. They should retain
the same specificity as the parent antibody, but by virtue of
their much lower molecular weights may be found to have
greater pentrative powers. Investigation of the value of anti-
body fragments will form the next phase of our investiga-
tions.
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